AR and benign prostatic hyperplasia: In summary, BPH have more AR-V4 (which could activate both AR-V7 and AR-FL pathways), primary PCa have more AR-V1 (to activate AR-FL canonical targets and inhibit AR-V7), and CRPC, according to the literature, have more AR-V7 (castration-resistant cell growth driver).